“In addition to its deep bench of expertise in mass production of complex technologies, Jabil’s footprint in Ireland and around the world will be vital in helping us accelerate availability of the CovidNudge test globally, and in enabling DnaNudge to offer to the mass market a rapid, accurate near-patient testing solution that has the potential to transform the pandemic response worldwide,” said Toumazou.
The CovidNudge test uses the gold-standard RT-PCR technique to test for the presence of the genetic material of the COVID-19 virus. The cartridge – manufactured by Jabil – can extract RNA from a naso-pharyngeal, nasal or buccal swab (inner cheek swab) sample, which is then inserted into the NudgeBox for analysis and reverse transcribing to DNA.
“The availability of rapid, high-accuracy testing performed at the point of patient specimen collection is a vital tool amid this COVID-19 pandemic that continues to spread,” said VP Global Business Units, Jabil, David Panneton. “We are thrilled to support DnaNudge’s efforts in the UK and globally and to apply our full healthcare manufacturing and supply chain solution set to meet this critical market demand.”
Related Covid-19 test articles
- WORLD FIRST WITH MACHINE FOR MULTIPLE TESTS
- PANDEMIC RESHAPES MICROFLUIDICS MARKET
- PRODUCTION STARTS FOR 20s OPTICAL VIRUS TEST
- ANALOG DEVICES EXTENDS DESKTOP DNA WRITER DEAL
- EVONETIX PARTNERS WITH IMEC ON MEMS-BASED SYNTHESIS PLATFORM
Other articles on eeNews Europe